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**Abstract**

**Background:** The relationship between severe inflammation and clinical depression in the context of major medical illnesses has been addressed, but the relationship between mild infections/inflammation and clinical depression is unclear. We aimed to examine whether a history of repeated low-grade infections/inflammation (RLGI) in medically healthy subjects (MHS) could increase the vulnerability to major depressive disorder (MDD) and whether RLGI could be associated with higher resistance to antidepressants in those developing MDD.

**Methods:** A nationwide population-based cohort study (1996--2011) was conducted for MHS with and without a history of RLGI. The rates of MDD during an up to 8-year follow-up period were compared between the two groups in two independent cohorts. The stratified responses to antidepressants, including easy-to-treat and difficult-to-treat responses, were also compared in the MDD patients.

**Results:** During the follow-up, the two cohorts consistently revealed that the RLGI(+) group had a significantly higher chance of developing MDD over time than the RLGI(-) group. Cox-PH regression models showed that the hazard ratio associated with a history of RLGI was 1.369 to 1.911 (*p*\<0.001), after adjusting for confounding factors. MDD patients in the RLGI(+) group consistently presented higher ratios of difficult-to-treat responses to sequential antidepressant trials in adequate doses than those in the RLGI(-) group (cohort-2002: 11.5% vs. 7.6%; cohort-2004: 11.8% vs. 4.3%, both p\<0.05).

**Conclusion:** This is the first large-scale study to report a reliable temporal association between a history of RLGI and subsequent diagnosis of MDD and poor responses to antidepressants. Our dada support the view that chronic inflammation plays a role in the pathophysiology of MDD and antidepressant-resistant depression.
